Next generation lung fluid management technology for heart failure launched

Published On 2019-09-16 13:40 GMT   |   Update On 2019-09-16 13:40 GMT

A next-generation lung fluid management technology for heart failure has been launched at the Heart Failure Society of America conference in Philadelphia, PA. The new system ReDSTM PRO is a useful tool for assessment of my heart failure patients' pulmonary congestion. It utilizes RF technology that produces reliable fluid volume readings after 45 seconds of measurement and the system can be utilized across the continuum of hospital care, from the emergency department to discharge and subacute rehabilitation. The system will go a long way in helping improve heart failure care.


Lung fluid administration is an important component of the management of critically ill patients with acute heart failure. Congestion, or fluid overload, is a classic clinical feature of patients presenting with heart failure patients, and its presence is associated with adverse outcome.


Sensible Medical Innovations today announced the launch of the ReDSTM PRO system. The debut of the new system was at the Heart Failure Society of America conference in Philadelphia, PA. ReDSTM PRO is optimized for the Point-of-Care, designed for use in hospitals and sub-acute facilities. ReDSTM PRO utilizes non-invasive low energy RF technology that produces reliable fluid volume readings after 45 seconds of measurement. The ReDSTM PRO can be utilized across the continuum of hospital care, from the emergency department to discharge and subacute rehabilitation.


"ReDS is a valuable tool for assessment of my heart failure patients' pulmonary congestion," said Dr. Daniel Bensimhon, Medical Director of the Advanced Heart Failure and Mechanical Circulatory Support Program at Cone Health System in Greensboro, NC. "Having an unambiguous number to treat through discharge and follow up helps to manage the treatment. It's the fifth vital sign of Heart Failure."


"We are very excited to launch the ReDS Pro system here at HFSA," said Amir Ronen, Sensible Medical CEO. "The development of ReDS Pro optimized for the high throughput environment of a hospital is a huge milestone for our company and our customers. Expanding the accessibility to ReDS monitoring technology to help improve heart failure care is our goal and our passion."

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News